Oxford Nanopore Technolo... Share Discussion Threads

[bamboo2] 12/12/2021 16:07

Nanopore Community Meeting 2021 collection

Date: Tuesday 14th December
Time: 9:00 am (CST) | 10:00 am (JST) | 12:00 pm (AEST)
Location: online

A chance to watch a selection of talks from the Nanopore Community Meeting 2021 online, with live Q&A following each talk. We will hear from four scientists about their research using nanopore sequencing. The event will close with an update from Oxford Nanopore Technologies.

Rosemary Dokos will present an update which will include information about Kit 12 & R10.4 flow cells for >99% raw read & around Q30 (99.9%) Duplex sequencing accuracy, & the development of P2.



=====================================

[bamboo2] 10/12/2021 20:05

This week, ONT kit has been used worldwide to track the Omicron variant.

This link takes you to a fascinating timeline of events since covid was first sequenced in early 2020



The C-19 ONT community timeline is a perfect example of how the scientific community often turns to Twitter for speedy information dispersal.

[bamboo2] 10/12/2021 19:55

A quick [less than 2 min] video shows how ONT kit tackles Detecting DNA methylation in the human genome, compared with traditional [older] SBS kit [ala ILMN/PACB]

[bamboo2] 10/12/2021 19:48

Further to the recent community meeting tech announcements, scientists on twitter confirming some startlingly good results. eg,

Q30 consensus reads ~15-20Kb are great, however ~20-100Kb Q30 @nanopore duplex reads are truly disruptive. Shown is a 90Kb Ear of maizeR10.4 duplex read with 99.94% identity...

...Alexander Wittenberg@AW_NGS 1h

Okay last one for today. ~122 Kb near perfect (99.94% identity)

[johnrxx99] 07/12/2021 04:47

Certainly agree with the last para. Thanks B2

[bamboo2] 06/12/2021 17:02

John, I have thought more about the idea of Oxford nanopore machines being copied.

The pace of technological advance is so rapid, in the hardware, the software, the flowcell and the chemistry, that, for the foreseeable, I just don't think it it possible.

Putting patent issues aside, the economics don't stack up with the market nowhere near large and mature enough to be of interest to mass manufacturers. Any machine copied and made available would be out of date in under two years. An ONT device can effectively upgraded, or traded in as updates become standard. This would probably not be the case with a cheaper copy.

As I said before, compared with the SBS type offering from ILMN and PACBIO, ONT is already significantly cheaper and more functional.

Customers and clients around the world are professional users. Govts, Pharma's, Researchers, Universities and the like are typically not concerned about buying the cheapest tools they can get. More important is reliability, good results and useful conclusions.

[bamboo2] 03/12/2021 18:07

Target prices for these two not yet confirmed, but could confirm unless we see a sharp intraday reversal.

ILMN [sp $343] set to confirm a Double Top with a tp approx $260-270 [Hist support $336.50] [TP confirmed]
PACB [sp $20.15] set to confirm a bump and run top tp approx $11.20-12.20 [Hist support $14.00]
[PACB confirmed tp for bart a while ago. Currently at hist support $20.20]

[bamboo2] 03/12/2021 15:34

This is a recording of Clive Brown's NCM update 2021



00:00 Disclaimer
00:05 Introduction
01:00 Our goal
01:20 How nanopore sequencing works
06:44 Read length == Fragment length
09:25 Short fragment mode
12:40 Accuracy — Recap
14:48 Q20+ raw read accuracy
18:01 Accuracy — Where are we now?
21:50 Accuracy — Continuous improvement
25:05 Duplex — Reading both strands
31:01 Accuracy — Methylation
37:09 Accuracy — Enzyme kinetics
38:15 Accuracy — R10.4 and longer nanopores
39:44 The relationship between accuracy, speed and temperature
41:50 Chemistries — Movement schemes
45:26 Chemistries — Outy sequencing
54:02 Chemistries — Outy adaptive accuracy, highly accurate sequencing of rare single-molecules
56:57 Liquid biopsy workflow
59:04 Skunkworx: liquid biopsy devices
1:02:30 P2
1:03:50 P2 solo
1:04:47 Browser calling: web based basecalling
1:07:33 MinION Mk1D
1:10:50 Accuracy headlines
1:12:05 Org .one

Part two. More detail!
James Clarke, Stuart Reid and Rosemary Sinclair Dokos


00:00 Disclaimer
00:15 Introduction to technology & our goal
01:00 Why nanopore? And accuracy improvements
04:43 How does nanopore sequencing work?
05:47 How can we drive improvements in accuracy and output
08:05 The Nanopore product family
08:35 Accuracy improvements — From the R10.3 to R10.4 nanopores
09:19 PromethION accuracy improvements
09:57 PromethION output (10 Tb of data from a single run)
10:57 Marathon chips: design changes to PromethION Flow Cells
12:41 P2: Low-cost, high-throughput sequencing
13:52 Introduction to Flongle
16:10 Development of our low-cost Flongle Flow Cell
18:05 Can we remove the need for users to flush their flow cell in the future?
19:06 New ASIC and future applications
22:35 Innovation at Oxford Nanopore and how we do it
23:31 Accuracy — the different ways of thinking
24:54 What can affect accuracy?
25:40 A history of nanopore accuracy
27:03 Accuracy — where are we now?
27:38 Duplex accuracy
28:37 Consensus accuracy
29:20 Variant calling accuracy
31:38 Methylation accuracy & our new tool, Remora
33:19 Check out our results with our open data sets
33:51 Application accuracy: barcoding
34:28 Application accuracy: plants
35:40 Application accuracy: short fragments
36:44 Headline accuracy numbers
37:36 MinKNOW
39:15 Basecalling
40:10 Adaptive sampling
41:25 Platform updates
41:45 Platform scalability and accessibility
42:55 Price per Gb
43:31 The versatility and richness of information
46:06 Real, real- time
46:42 Product release process and continuous improvement
49:50 R.10.4 Nanopore and Kit 12 for Q20+ accuracy
50:34 Sample preparation and new kits
51:20 Native barcode kit for Q20+ chemistry
52:03 Rapid kit for Q20+ chemistry
52:35 Multiplex ligation kit
53:25 Ultra-long sequencing kit
54:25 Adaptive sampling
55:15 cDNA PCR sequencing kit
55:14 cDNA PCR sequencing kit: single cell sequencing
57:18 Midnight (ARTIC) sequencing kit
57:49 Sequencing short fragments
58:52 VolTRAX
59:19: Sequencing devices
59:37 MinION
1:00:25 PromethION
1:03:20 P2 Solo
1:03:55 Analysis updates
1:06:04 Tools and workflows
1:07:49 Release timeline

[bamboo2] 03/12/2021 12:48

Slightly more accessible version of the recent tech update.


Oxford Nanopore Announces Technology Updates - Dec 02, 2021
Published: Dec 02, 2021

OXFORD, UK / ACCESSWIRE / December 2, 2021 / Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer

Oxford, UK: Oxford Nanopore has provided a technology update at its Nanopore Community Meeting, describing a range of product releases and upgrades. These include the release of "Kit 12", a new kit that includes the latest "Q20+" chemistry and enables "Duplex" sequencing. This is coupled with the release of R10.4 flow cells. Users of nanopore sequencing can now achieve >Q20 raw read/"simplex" accuracy or around Q30 Duplex accuracy, and enhanced, high-accuracy consensus sequencing and variant calling, using these released products.

The Company has also announced PromethION 2 (P2), a device that can run up to two high-throughput PromethION Flow Cells, which will be available in starter packs from US$10,455. The P2 is designed to bring low-cost nanopore sequencing for large genomes or high-throughput long-read transcriptomics, without the requirement for capital investment and with minimal infrastructure requirement. P2 will be available as a standalone device with integrated compute, or "P2 Solo", a sequencing device that can be connected to existing compute, including GridION. P2 Solo will be shipped from Q2 2022 and Oxford Nanopore is now taking pre orders here.

Oxford Nanopore also introduced Remora, a new tool for methylation analysis. Remora further enhances base-modification analysis, and is used during the experiment (concurrent to standard basecalling), at no additional cost, while maintaining high-accuracy basecalling of native bases. Remora provides industry-leading performance at only 20X coverage.

"Short fragment mode" (SFM), to optimise accurate, high-throughput sequencing of shorter fragments as short as 20 bp, will be fully enabled in the new year. Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. However, software output settings have historically avoided shorter "adapter only" reads. SFM is designed to optimise applications where larger volumes of shorter fragments require high-accuracy analysis, supporting as many as 250M native human reads, at ~200 bp, on a PromethION flow cell.

"Path to in-field liquid biopsy". R&D pipeline programmes were reviewed, including chemistries such as "inny" and "outy", that capture a single molecule of DNA and make multiple measurements of that single molecule. These techniques have the potential to deliver "Adaptive Accuracy" - supporting capture and re-reading of rare variants in a mixed sample. could be paired with liquid biopsy workflows in the lab or in the field, potentially enabling easy-to-use remote "liquid biopsy" sequencing.

The Company is developing an integrated sequencer and tablet; the MinION Mk1D, that would be capable of processing the high data volumes produced by MinION and could be used for this purpose.

[bamboo2] 03/12/2021 10:11

Hi john, thanks. I have held GROW before. It looks solid. The only reason I am not holding at the moment is that Halifax SD do not allow it in a S&S ISA, but I am in the process of transferring to another provider, so hope to add those in the future.

[johnrxx99] 03/12/2021 03:47

Thanks B2 - I have GROW so fully stacked on incubators. Cheers and gl

[bamboo2] 02/12/2021 16:27

You can hear a short talk from Alex Wittenberg later on this afternoon. [17:20 GMT]

Here's the latest few from twitter...

Pinned Tweet
Alexander Wittenberg
@AW_NGS
·
1 Dec
Q30 consensus reads ~15-20Kb are great, however ~20-100Kb Q30 @nanopore duplex reads are truly disruptive. Shown is a 90Kb Ear of maizeR10.4 duplex read with 99.94% identity against golden reference B73 NAM v5.0 #nanoporeconf #accuracy #crops
·
2h
Replying to
@AW_NGS
and
@PacBio
Mmm .... Seems that ONT could give PacBio a Hard Time in 2022 ....
Alexander Wittenberg
@AW_NGS
·
2h
Just running some more Ear of maize duplex cells. Below some hot of the press (not whole dataset) results of R10.4/LSK112. 99.9% median accuracy. Not only @PacBio can generate HiFi reads.

[bamboo2] 02/12/2021 16:03

Bought the dip and put 2613 at 694 ish into sipp

john, it could happen, but most of the component parts are made by ONT themselves, and the machines are in no way overpriced, compared to the competition.

How about averaging in? Or get exposure to ONT [10.3%] by buying IPGroup, currently at a discount to NAV of approx 30%.

[johnrxx99] 02/12/2021 09:14

B2 - I have but....... I love the potential, and don't get me wrong but my main worry is its uncopyability. Knowing the Chinese, patents are irrelevant - how long before we hear about an Asian version of the tech?

[bamboo2] 02/12/2021 09:05

john, I do understand the dilemma. I have posted relevant info on the thread in an attempt to help understanding of the product. Might help some by doing an "ONT" search on the IPO thread, as this has some of the pre-flotation info.

[bamboo2] 02/12/2021 09:01

Sequencing in US for Omicron used ONT rather than SBS tech.



""Testing for the infection was done by a Color Health Inc. lab in San Francisco, according to an outside representative of the company. The strain was identified in less than 30 hours from sample collection. The sample was then turned over to the University of California, San Francisco lab of Charles Chiu for confirmatory sequencing.

Chiu said his laboratory heard about the sample on Tuesday afternoon and had received it by 8 p.m. From there, they ran a quick molecular test looking for what’s known as spike-gene dropout, which suggested the sample was possibly omicron.

Small Sequencer
To confirm the finding, the lab sequenced the entire genome of the virus using a pocket-sized sequencing machine made by Oxford Nanopore Technologies PLC. Within five hours, they had confirmed the detection of omicron, and within eight, the entire genome had been decoded.

“At 4 a.m. last night we were able to conclusively demonstrate that this was indeed an infection from the omicron variant,” he said in the press conference.""

[johnrxx99] 02/12/2021 08:56

B2 -= which is a worry to investors

[bamboo2] 02/12/2021 07:49

Ayl, there are aspects of this co. that as a non-biologist you have to accept you will not understand! However, if you learn a few NGS basics, and follow the timeline of the company, most of the announcements from yesterday become relevant.

The message is clear.

There is no longer a place for SBS type sequencing of the type offered by Illumina and PacBio.

==============================================

Take for example the new integrated sequencer and tablet; the MinION Mk1D. This is based on an Apple I-Pad.

It's a MinION, intergrated into an Apple I-Pad!
Picture here...


Two other standouts for the future were the Liquid Biopsy Platform, [This has a sample chamber above a detection chamber. The device accepts raw sample input with only minimal prep required.] and the 'Inny' 'Outy' Intelligent sequencing. [Multiple re-reads, in and out of the pore].

I will sum up the accuracy improvements as best as I can later on today or tomorrow.

[bamboo2] 02/12/2021 07:35

This is the RNS today.

Oxford Nanopore Technologies plc

02 December 2021

Oxford Nanopore announces technology updates at Nanopore Community Meeting

Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer

Oxford, UK: Oxford Nanopore has provided a technology update at its Nanopore Community Meeting, describing a range of product releases and upgrades. These include the release of "Kit 12", a new kit that includes the latest "Q20+" chemistry and enables "Duplex" sequencing. This is coupled with the release of R10.4 flow cells. Users of nanopore sequencing can now achieve >Q20 raw read/"simplex" accuracy or around Q30 Duplex accuracy, and enhanced, high-accuracy consensus sequencing and variant calling, using these released products.

The Company has also announced PromethION 2 (P2), a device that can run up to two high-throughput PromethION Flow Cells, which will be available in starter packs from US$10,455. The P2 is designed to bring low-cost nanopore sequencing for large genomes or high-throughput long-read transcriptomics, without the requirement for capital investment and with minimal infrastructure requirement. P2 will be available as a standalone device with integrated compute, or "P2 Solo", a sequencing device that can be connected to existing compute, including GridION. P2 Solo will be shipped from Q2 2022 and Oxford Nanopore is now taking pre orders here .

Oxford Nanopore also introduced Remora, a new tool for methylation analysis. Remora further enhances base-modification analysis, and is used during the experiment (concurrent to standard basecalling), at no additional cost, while maintaining high-accuracy basecalling of native bases. Remora provides industry-leading performance at only 20X coverage.

"Short fragment mode" (SFM), to optimise accurate, high-throughput sequencing of shorter fragments as short as 20 bp, will be fully enabled in the new year. Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. However, software output settings have historically avoided shorter "adapter only" reads. SFM is designed to optimise applications where larger volumes of shorter fragments require high-accuracy analysis, supporting as many as 250M native human reads, at 200 bp, on a PromethION flow cell.

"Path to in-field liquid biopsy" . R&D pipeline programmes were reviewed, including chemistries such as "inny" and "outy", that capture a single molecule of DNA and make multiple measurements of that single molecule. These techniques have the potential to deliver "Adaptive Accuracy" - supporting capture and re-reading of rare variants in a mixed sample. could be paired with liquid biopsy workflows in the lab or in the field, potentially enabling easy-to-use remote "liquid biopsy" sequencing.

The Company is developing an integrated sequencer and tablet; the MinION Mk1D , that would be capable of processing the high data volumes produced by MinION and could be used for this purpose.

Nanopore Community Meeting

The annual Nanopore Community Meeting, held online in 2021, has this year featured more than 50 user talks, spanning areas including human genetics, clinical / cancer research, microbiology including genomic epidemiology, plant and animal research and bioinformatics. Write ups and videos of the talks are made available on the nanopore website. At the meeting, Oxford Nanopore provided a technology update, featuring Clive G Brown (CTO) and talks from James Clarke, Stuart Reid and Rosemary Sinclair Dokos.

For a complete overview of these and more announcements, please visit Oxford Nanopore's website at

[ayl30] 02/12/2021 07:08

Last nights technical update sounds good but you need a biotec degree to understand it!

[bamboo2] 01/12/2021 23:05

Oxford Nanopore announces technology updates at Nanopore Community Meeting
Wed 1st December 2021

Nanopore Community Meeting, Oxford, UK

Highlights include release of new “Kit 12” and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer

Oxford Nanopore has provided a technology update at its Nanopore Community Meeting, describing a range of product releases and upgrades. These include the release of “Kit 12”, a new kit that includes the latest “Q20+” chemistry and enables “Duplex” sequencing. This is coupled with the release of R10.4 flow cells. Users of nanopore sequencing can now achieve >Q20 raw read/“simplex” accuracy or around Q30 Duplex accuracy, and enhanced, high-accuracy consensus sequencing and variant calling, using these released products.

The Company has also announced PromethION 2 (P2), a device that can run up to two high-throughput PromethION Flow Cells, which will be available in starter packs from US$10,455. The P2 is designed to bring low-cost nanopore sequencing for large genomes or high-throughput long-read transcriptomics, without the requirement for capital investment and with minimal infrastructure requirement. P2 will be available as a standalone device with integrated compute, or “P2 Solo”, a sequencing device that can be connected to existing compute, including GridION. P2 Solo will be shipped from Q2 2022 and Oxford Nanopore is now taking pre orders here.  

Oxford Nanopore also introduced Remora, a new tool for methylation analysis. Remora further enhances base-modification analysis, and is used during the experiment (concurrent to standard basecalling), at no additional cost, while maintaining high-accuracy basecalling of native bases. Remora provides industry-leading performance at only 20X coverage.

“Short fragment mode” (SFM), to optimise accurate, high-throughput sequencing of shorter fragments as short as 20 bp, will be fully enabled in the new year.  Oxford Nanopore’s technology sequences DNA or RNA molecules of any length, from short to ultra-long. However, software output settings have historically avoided shorter “adapter only” reads. SFM is designed to optimise applications where larger volumes of shorter fragments require high-accuracy analysis, supporting as many as 250M native human reads, at ~200 bp, on a PromethION flow cell.

“Path to in-field liquid biopsy”. R&D pipeline programmes were reviewed, including chemistries such as “inny” and “outy”, that capture a single molecule of DNA and make multiple measurements of that single molecule. These techniques have the potential to deliver “Adaptive Accuracy” – supporting capture and re-reading of rare variants in a mixed sample.  could be paired with liquid biopsy workflows in the lab or in the field, potentially enabling easy-to-use remote “liquid biopsy” sequencing.

The Company is developing an integrated sequencer and tablet; the MinION Mk1D, that would be capable of processing the high data volumes produced by MinION and could be used for this purpose.

Nanopore Community Meeting

The annual Nanopore Community Meeting, held online in 2021, has this year featured more than 50 user talks, spanning areas including human genetics, clinical / cancer research, microbiology including genomic epidemiology, plant and animal research and bioinformatics.̷9; Write ups and videos of the talks are made available on the nanopore website.  At the meeting, Oxford Nanopore provided a technology update, featuring Clive G Brown (CTO) and talks from James Clarke, Stuart Reid and Rosemary Sinclair Dokos.  In addition to the above, the following updates were presented:

Accuracy

Users can now choose between flow cells that use the R9.4.1 nanopore, paired with “Kit 10 or Kit 11”, which run at ~420 bases per second. They may also choose the new R10.4 nanopore, a newer design with longer reader head that is designed to provide high resolution of homopolymers and increased consensus accuracy. R10.4 is paired with the new Kit 12, which runs at ~230-270 bases per second.  ; Kit 12 enables the newest “Q20+” chemistry and “Duplex”, where two complementary molecules from the same Duplex strand are sequenced consecutively for higher accuracy. 

With an additional choice of basecalling modes, users can tailor their experiments to their requirements, and achieve greater than Q20/99% raw read accuracy on fully released products.  Single molecule Duplex read accuracies are distributed around Q30/99.9%, with the longest Q30 read demonstrated so far at 156 kbases (although there is no fundamental limit here).

This raw read accuracy performance provides the foundation for high consensus accuracy, which can reach Q50 (99.999%), and the ability to detect and characterise a range of genetic variants including single point mutations, structural variations and methylation throughout the entirety of the genome, for the most comprehensive genomic analysis. 

Oxford Nanopore provided an update on the latest analysis tools for optimised performance, including recommending Medaka for consensus accuracy of >Q50 (bacterial), Clair3 for SNP and Indel calling (F1 scores of 99.9% and 89% respectively, representative of whole genome performance) and LRA/CuteSV for structural variation (F1 96.1%).

Oxford Nanopore announced that base caller models now include native Plant DNA as part of their training, such that plant-specific base modifications present are recognised as canonical bases as opposed to errors, increasing the accuracy for users sequencing highly modified plants. Modifications can be recovered from the signal using Remora.

R&D/pipeline updates

A new upgrade of PromethION chip – the Marathon chip (M chip) – will be released in early 2022, providing greater output through extended run duration, and PromethION compute towers will also be upgraded for increased compute capacity

Potential pipeline chemistries were reviewed, including “inny” and “outy” and the potential to deploy “Adaptive accuracy” – real time sequencing until a target accuracy has been achieved, supporting high-accuracy sequencing of rare variants in single molecules, in a highly efficient way.
These pipeline chemistries have the potential to support ‘liquid biopsy’ workflows that could detect and analyse molecules from various samples such as blood, saliva or environmental samples, either in a lab environment or in the field. To accompany these chemistries, Oxford Nanopore is developing a mobile device designed to sequence direct from sample. No timeline has been provided for this device, which has the potential to also be adapted for other analytes such as small molecules.

Progress was announced in the development of a low-cost flow cell for Flongle, using a polymer substrate instead of silicon. With proof of concept at 120 nanopores per chip, on which 2 Gb of data has been generated.  This design is now being moved into a prototype manufacturing phase.

The first sequencing data was presented from the new generation ASIC, a new, smaller, low power and low noise design of electronic chip designed to drive the development of new products such as the SmidgION sequencer for mobile phone or Plongle desktop “array sequencer”.

Product updates

Multiple sample preparation updates were provided:

The launch of Kit 12 and R10.4 for highest accuracy sequencing is complemented by a native barcoding kit so that the Q20+ chemistry can be multiplexed, and is also compatible with the rapid kit for Q20+

The Monarch NEB ultra-long sequencing protocol was launched in the summer to enable ultra-long read sequencing, compatible with protocols on cell and blood and now tissue extraction.

For high-throughput sequencing on PromethION, the new multiplex ligation kit is now in Early Access and is intended to deliver two human genomes per PromethION flow cell with the capacity to sequence up to 96 samples using the latest barcoding kits

Automation for high throughput sequencing operations is being further developed, including Hamilton script for two genomes per PromethION flow cell

VolTRAX devices that are PCR-enabled are now shipping to customers

The Midnight kit, for sequencing SARS-COV-2 for COVID surveillance, in 5.5 hours and for as little as $9.55, was launched in the summer. It continues to detect Omicron and successfully identify lineage.  Further updates are bring provided to users in response to the evolving COVID situation

The rapid/field kits can now support inputs of 50-100 ng of DNA, down from 400 ng; this improvement is being developed for the whole range

The new cDNA PCR kit is also launched, which can deliver more than 20M 1 kb reads on MinION flow cells and over 160M reads on PromethION flow cells. This kit also simplifies single-cell transcriptome analysis, with the ability to deliver full-length reads for isoform discovery/characterisation, gene fusions, cell-subtype analysis or spatial profiling

Adaptive Sampling is a unique feature of Oxford Nanopore sequencing platforms, enabling real-time selection of DNA regions of interest. In addition to target enrichment, Oxford Nanopore also demonstrated reduced representation methylation sequencing using MinKNOW. The ability to obtain 6 million CpGs from a single MinION run, represents superior performance to bisulfite methods, with the usual nanopore benefits of simple workflow, low cost and time-to result.

Updates were provided on developments in software, including the expansion of EPI2ME into regional areas, to support broader access to ‘plug-and-play’ analysis workflows

Watch the Nanopore Community Meeting technology update video for more information.

[bamboo2] 01/12/2021 20:39

Is anyone else listening to this???

:-)))

[bamboo2] 01/12/2021 16:35

The update from Oxford Nanopore Technologies at 8:05pm gmt [this evening] should be interesting, and feature info on new products that will be of interest to investors. These sessions are normally recorded, and can be viewed after the event.

It features...

1/ Clive Brown, Clive is Chief Technology Officer at Oxford Nanopore Technologies. On the Executive team, he is responsible for all of the Company’s product-development activities. Clive leads the specification and design of the Company’s nanopore-based sensing platform, primarily strand DNA/RNA sequencing, with a strong focus on scientific excellence and successful adoption by the scientific community.

Clive joined Oxford Nanopore Technologies from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of next-generation DNA sequencing platforms. This involved helping to set up the world’s largest single installation of Illumina (formerly Solexa) Genome Analyzers in a production sequencing environment, initially used to pioneer the 1000 Genomes Project.

From early 2003 he was Director of Computational Biology and IT at Solexa Ltd, where he was central to the development and commercialisation of the Genome Analyzer (GA). Solexa was sold to Illumina for $650m in early 2007 after the successful placement and adoption of 12 instruments. The Solexa technology, now commercialised by Illumina, is the market-leading DNA sequencing technology driving the renaissance in DNA-based discovery.

He has a strong background in computer science and genetics/molecular biology and manages interdisciplinary teams including mechanical engineering, electronics, physics, surface chemistry, electrophysiology, software engineering and applications (of the technology). Clive applies modern agile management techniques to the entire product-development lifecycle.

Clive has also held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations. He has worked at the interface between computing and science, ranging from genetics to proteomics. He holds degrees in Genetics and Computational Biology from the University of York.

2/ James Clarke, responsible for the Research Division at Oxford Nanopore. [mainly Chemistry]

3/ Stuart Reid, VP of Development at Oxford Nanopore. Stuart is responsible for the specification, performance and delivery of the company’s nanopore-based sensing products and applications into the marketplace.

4/ Rosemary Sinclair Dokos leader of the Product Management team that enables the release of novel products and improvements into the field. She has over 10 years of experience in the Life Science market, covering Genomics, Proteomics and Cell Biology.

[bamboo2] 01/12/2021 15:57

tonsil, did you want a link to the conference?

Try this...



You need to register for the community first to get log in details sorted, takes a moment, then a short form to tick some boxes.

There is a section later on at 8.05pm gmt that should give some idea of updates and new developments.